Phoenix Bio

研究開発

研究開発

A Novel Orally Available Small Molecule That Inhibits Hepatitis B Virus Expression

    Mueller, H. Wildum, S. Luangsay, S. Walther, J. Lopez, A. Tropberger, P. Ottaviani, G. Lu, W. John Parrott, N. Zhang, J. D. Schmucki, R. Racek, T. Hoflack, J. C. Kueng, E. Point, F. Zhou, X. Steiner, G. Lutgehetmann, M. Rapp, G. Volz, T. Dandri, M. Yang, S. Young, J. A. T. Javanbakht, H.

    J Hepatol. 2017 Oct 24. pii: S0168-8278(17)32393-0. doi: 10.1016/j.jhep.2017.10.014.

    Efficacy of NVR 3-778, Alone and in Combination With Pegylated Interferon, vs Entecavir in uPA/SCID Mice With Humanized Livers and HBV Infection

      Klumpp, K. Shimada, T. Allweiss, L. Volz, T. Lutgehetmann, M. Hartman, G. Flores, O. A. Lam, A. M. Dandri, M.

      Gastroenterology. 2017 Oct 24. pii: S0016-5085(17)36276-5. doi: 10.1053/j.gastro.2017.10.017.

      Highly specific delivery of siRNA to hepatocytes circumvents endothelial cell-mediated lipid nanoparticle-associated toxicity leading to the safe and efficacious decrease in the hepatitis B virus

        Sato, Y. Matsui, H. Yamamoto, N. Sato, R. Munakata, T. Kohara, M. Harashima, H.

        J Control Release. 2017 Oct 3;266:216-225. doi: 10.1016/j.jconrel.2017.09.044.

        Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages

          Cheng, X. Xia, Y. Serti, E. Block, P. D. Chung, M. Chayama, K. Rehermann, B. Liang, T. J.

          Hepatology. 2017 Jun 30. doi: 10.1002/hep.29348.

          Development of a Novel Site-Specific Pegylated Interferon Beta for Antiviral Therapy of Chronic Hepatitis B Virus

            Tsuge, M. Uchida, T. Hiraga, N. Kan, H. Makokha, G. N. Abe-Chayama, H. Miki, D. Imamura, M. Ochi, H. Hayes, C. N. Shimozono, R. Iwamura, T.Narumi, H. Suzuki, T  Kainoh, M. Taniguchi, T.

            Antimicrob Agents Chemother. 2017 May 24;61(6).

            The Smc5/6 Complex Restricts HBV when Localized to ND10 without Inducing an Innate Immune Response and Is Counteracted by the HBV X Protein Shortly after Infection

              Niu, C. Livingston, C. M. Li, L. Beran, R. K. Daffis, S. Ramakrishnan, D. Burdette, D. Peiser, L. Salas, E. Ramos, H. Yu, M. Cheng, G. Strubin, M. Delaney Iv, W. E. Fletcher, S. P.

              PLoS One. 2017 Jan 17;12(1):e0169648.

              Hepatitis B virus X protein identifies the Smc5/6 complex as a host restriction factor

                Decorsiere, A. Mueller, H. van Breugel, P. C. Abdul, F. Gerossier, L. Beran, R. K. Livingston, C. M. Niu, C. Fletcher, S. P. Hantz, O. Strubin, M.

                Nature. 2016 Mar 17;531(7594):386-9. doi: 10.1038/nature17170.

                Persistent Loss of HBV Markers in Serum without Cellular Immunity by Combination of PEG-IFN Plus ETV Therapy in Humanized Mice

                  Uchida, T. Imamura, M. Hayes, C. N. Hiraga, N. Kan, H. Tsuge, M. Abe-Chayama, H. Zhang, Y. Makokha, G. N. Aikata, H. Miki, D. Ochi, H. Ishida, Y. Tateno, C. Chayama, K.

                  Antimicrob Agents Chemother. 2017 Jul 10. pii: AAC.00725-17. doi: 10.1128/AAC.00725-17

                  Transmission of HBV DNA Mediated by Ceramide-Triggered Extracellular Vesicles

                    Sanada,Takahiro1,*  Hirata, Yuichi1,* Naito, Yutaka 2,  Yamamoto,Naoki1,  Kikkawa, Yoshiaki3, Ishida, Yuji 4,  Yamasaki,Chihiro 4,  Tateno, Chise 4,  Ochiya, Takahiro 2 and  Kohara, Michinori 1

                    Cell Mol Gastroenterol Hepatol. 2016 Oct 24;3(2):272-283.

                    Cyclosporin derivatives inhibit hepatitis B virus entry without interfering with NTCP transporter activity

                      Shimura, S. Watashi, K. Fukano, K. Peel, M. Sluder, A. Kawai, F. Iwamoto, M. Tsukuda, S. Takeuchi, J. S. Miyake, T. Sugiyama, M. Ogasawara, Y. Park, S. Y. Tanaka, Y. Kusuhara, H. Mizokami, M. Sureau, C. Wakita, T.

                      J Hepatol. 2016 Nov 24. pii: S0168-8278(16)30683-3. doi: 10.1016/j.jhep.2016.11.009.

                      A new class of hepatitis B and D virus entry inhibitors, proanthocyanidin and its analogs, that directly act on the viral large surface proteins

                        Tsukuda, S. Watashi, K. Hojima, T. Isogawa, M. Iwamoto, M. Omagari, K. Suzuki, R. Aizaki, H. Kojima, S. Sugiyama, M. Saito, A. Tanaka, Y. Mizokami, M. Sureau, C. Wakita, T.

                        Hepatology. 2016 Nov 18. doi: 10.1002/hep.28952.

                        Inhibitory effect of CDK9 inhibitor FIT-039 on hepatitis B virus propagation

                          Tanaka, T. Okuyama-Dobashi, K. Murakami, S. Chen, W. Okamoto, T. Ueda, K. Hosoya, T. Matsuura, Y. Ryo, A. Tanaka, Y. Hagiwara, M. Moriishi, K.

                          Antiviral Res. 2016 Aug 8. pii: S0166-3542(16)30357-6.

                          新規核酸アナログ4′-C-cyano-2′-deoxyadenosine, 4′-C-cyano-2′-deoxyguanosineは薬剤耐性B型肝炎ウイルス変異種に対して有効である(短報)

                          林 佐奈衣、高松悠樹、前田賢次、村上周子,尾曲克已、松居剛志、五十川正記、渡邊網正、狩野吉康、向後悟、濱屋裕明、田中靖人

                          肝臓 2016; 57(6):299-301

                          Antiviral effects of anti-HBs immunoglobulin and vaccine on HBs antigen seroclearance for chronic hepatitis B infection

                            Tsuge, M. Hiraga, N. Uchida, T. Kan, H. Miyaki, E. Masaki, K. Ono, A. Nakahara, T. Abe-Chayama, H. Zhang, Y. Naswa, M. G. Kawaoka, T. Miki, D. Imamura, M. Kawakami, Y. Aikata, H. Ochi, H. Hayes, C. N. Chayama, K.

                            J Gastroenterol. 2016 Mar 4.

                            Possible Involvement of Hepatitis B Virus Infection of Hepatocytes in the Attenuation of Apoptosis in Hepatic Stellate Cells

                              Sasaki, R. Kanda, T. Nakamura, M. Nakamoto, S. Haga, Y. Wu, S. Shirasawa, H. Yokosuka, O.

                              PLoS One. 2016 Jan 5;11(1):e0146314. doi: 10.1371/journal.pone.0146314. eCollection 2016.

                              A Novel Tricyclic Polyketide, Vanitaracin A, Specifically Inhibits the Entry of Hepatitis B and D Viruses by Targeting Sodium Taurocholate Cotransporting Polypeptide

                                Kaneko, M. Watashi, K. Kamisuki, S. Matsunaga, H. Iwamoto, M. Kawai, F. Ohashi, H. Tsukuda, S. Shimura, S. Suzuki, R. Aizaki, H. Sugiyama, M. Park, S. Y. Ito, T. Ohtani, N. Sugawara, F. Tanaka, Y. Mizokami, M. Sureau, C. Wakita, T.

                                J Virol. 2015 Dec;89(23):11945-53. doi: 10.1128/JVI.01855-15.

                                ヒト肝細胞キメラマウスを用いたin vivoおよびin vitro HBV感染モデル

                                石田雄二、横道博、加国雅和、立野知世

                                新ウイルス性肝炎学 2015 page386-391

                                Human Cytotoxic T Lymphocyte-Mediated Acute Liver Failure and Rescue by Immunoglobulin in Human Hepatocyte Transplant TK-NOG Mice

                                  Uchida, T. Hiraga, N. Imamura, M. Tsuge, M. Abe, H. Hayes, C. N. Aikata, H. Ishida, Y. Tateno, C. Yoshizato, K. Ohdan, H. Murakami, K. Chayama, K.

                                  J Virol. 2015 Oct;89(19):10087-96. doi: 10.1128/JVI.01126-15. Epub 2015 Aug 5.

                                  Novel pH-sensitive multifunctional envelope-type nanodevice for siRNA-based treatments for chronic HBV infection

                                    Yamamoto, N. Sato, Y. Munakata, T. Kakuni, M. Tateno, C. Sanada, T. Hirata, Y. Murakami, S.  Tanaka, Y. Chayama, K. Hatakeyama, H. Hyodo, M. Harashima, H. Kohara, M.

                                    J Hepatol. 2015 Oct 23. pii: S0168-8278(15)00713-8. doi: 10.1016/j.jhep.2015.10.014.

                                    Effect of tenofovir disoproxil fumarate on drug-resistant HBV clones

                                      Murakami, E. Tsuge, M. Hiraga,  N.Kan, H. Uchida, T. Masaki, K. Nakahara, T. Ono, A. Miki, D. Kawaoka, T. Abe, H.Imamura, M. Aikata, H. Ochi, H. Hayes, C. N. Akita, T. Tanaka, J. Chayama, K.

                                      J Infect. 2015 Oct 26. pii: S0163-4453(15)00339-4. doi: 10.1016/j.jinf.2015.09.038.